Morphic announces corporate highlights and third quarter 2021 financial results

Morf-057 phase 1 safety, receptor occupancy, pk and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1q22
MORF Ratings Summary
MORF Quant Ranking